Cited 0 times in Scipus Cited Count

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

DC Field Value Language
dc.contributor.authorLee, B-
dc.contributor.authorChang, SJ-
dc.contributor.authorKwon, BS-
dc.contributor.authorSon, JH-
dc.contributor.authorLim, MC-
dc.contributor.authorKim, YH-
dc.contributor.authorLee, SW-
dc.contributor.authorChoi, CH-
dc.contributor.authorEoh, KJ-
dc.contributor.authorLee, JY-
dc.contributor.authorSuh, DH-
dc.contributor.authorKim, YB-
dc.date.accessioned2024-02-13T23:27:09Z-
dc.date.available2024-02-13T23:27:09Z-
dc.date.issued2024-
dc.identifier.issn2005-0380-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32206-
dc.description.abstractSince the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.-
dc.language.isoen-
dc.subject.MESHBevacizumab-
dc.subject.MESHCarcinoma, Ovarian Epithelial-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHOvarian Neoplasms-
dc.subject.MESHRepublic of Korea-
dc.titleClinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines-
dc.typeArticle-
dc.identifier.pmid38178704-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792210-
dc.subject.keywordBevacizumab-
dc.subject.keywordCytoreductive Surgery-
dc.subject.keywordEpithelial Ovarian Cancer-
dc.subject.keywordIntraperitoneal Chemotherapy-
dc.subject.keywordPoly (ADP-ribose) Polymerase Inhibitor-
dc.subject.keywordSurvival-
dc.contributor.affiliatedAuthorChang, SJ-
dc.contributor.affiliatedAuthorSon, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.3802/jgo.2024.35.e43-
dc.citation.titleJournal of gynecologic oncology-
dc.citation.volume35-
dc.citation.number1-
dc.citation.date2024-
dc.citation.startPagee43-
dc.citation.endPagee43-
dc.identifier.bibliographicCitationJournal of gynecologic oncology, 35(1). : e43-e43, 2024-
dc.identifier.eissn2005-0399-
dc.relation.journalidJ020050380-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
38178704.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse